Department of Surgery, Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, TN, USA.
HPB (Oxford). 2011 Nov;13(11):783-91. doi: 10.1111/j.1477-2574.2011.00355.x. Epub 2011 Aug 19.
The optimal strategy for treating hepatocellular carcinoma (HCC), a disease with increasing incidence, in patients with Child-Pugh class A cirrhosis has long been debated. This study evaluated the cost-effectiveness of hepatic resection (HR) or locoregional therapy (LRT) followed by salvage orthotopic liver transplantation (SOLT) vs. that of primary orthotopic liver transplantation (POLT) for HCC within the Milan Criteria.
A Markov-based decision analytic model simulated outcomes, expressed in costs and quality-adjusted life years (QALYs), for the three treatment strategies. Baseline parameters were determined from a literature review. Sensitivity analyses tested model strength and parameter variability.
Both HR and LRT followed by SOLT were associated with earlier recurrence, decreased survival, increased costs and decreased quality of life (QoL), whereas POLT resulted in decreased recurrence, increased survival, decreased costs and increased QoL. Specifically, HR/SOLT yielded 3.1 QALYs (at US$96 000/QALY) and LRT/SOLT yielded 3.9 QALYs (at US$74 000/QALY), whereas POLT yielded 5.5 QALYs (at US$52 000/QALY). Sensitivity analyses supported these findings at clinically meaningful probabilities.
Under the Model for End-stage Liver Disease (MELD) system, in patients with HCC within the Milan Criteria, POLT increases survival and QoL at decreased costs compared with HR or LRT followed by SOLT. Therefore, POLT is the most cost-effective strategy for the treatment of HCC.
对于伴有发病率不断增加的肝硬化 A 级患者,如何治疗肝细胞癌(HCC)一直存在争议。本研究评估了米兰标准内 HCC 患者行肝切除术(HR)或局部区域治疗(LRT)联合挽救性原位肝移植(SOLT)与直接行原位肝移植(POLT)的成本效益。
采用马尔可夫决策分析模型模拟三种治疗策略的结局,以成本和质量调整生命年(QALY)表示。基线参数来自文献复习。敏感性分析测试了模型的强度和参数的变异性。
HR 和 LRT 联合 SOLT 均与更早的复发、更低的生存率、更高的成本和更低的生活质量(QoL)相关,而 POLT 则与更低的复发、更高的生存率、更低的成本和更高的 QoL 相关。具体而言,HR/SOLT 产生 3.1 个 QALY(成本为 96000 美元/QALY),LRT/SOLT 产生 3.9 个 QALY(成本为 74000 美元/QALY),而 POLT 产生 5.5 个 QALY(成本为 52000 美元/QALY)。在具有临床意义的概率下,敏感性分析支持这些发现。
在终末期肝病模型(MELD)系统下,对于米兰标准内的 HCC 患者,与 HR 或 LRT 联合 SOLT 相比,POLT 以较低的成本提高了生存率和 QoL,因此是治疗 HCC 的最具成本效益的策略。